These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 32328144)

  • 1. Corrigendum to "The Effect of a Hydrolyzed Polysaccharide Dietary Supplement on Biomarkers in Adults with Nonalcoholic Fatty Liver Disease".
    Lewis JE; Atlas SE; Higuera OL; Fiallo A; Rasul A; Farooqi A; Kromo O; Lantigua LA; Tiozzo E; Woolger JM; Goldberg S; Mendez A; Rodriguez AE; Konefal J
    Evid Based Complement Alternat Med; 2020; 2020():9575878. PubMed ID: 32328144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effect of a Hydrolyzed Polysaccharide Dietary Supplement on Biomarkers in Adults with Nonalcoholic Fatty Liver Disease.
    Lewis JE; Atlas SE; Higuera OL; Fiallo A; Rasul A; Farooqi A; Kromo O; Lantigua LA; Tiozzo E; Woolger JM; Goldberg S; Mendez A; Rodriguez AE; Konefal J
    Evid Based Complement Alternat Med; 2018; 2018():1751583. PubMed ID: 29853945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Corrigendum to "Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease".
    Masarone M; Rosato V; Dallio M; Gravina AG; Aglitti A; Loguercio C; Federico A; Persico M
    Oxid Med Cell Longev; 2021; 2021():9757921. PubMed ID: 34373772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Corrigendum to "Caffeoylquinic Acid-Rich Extract of
    Lee YJ; Jang YN; Han YM; Kim HM; Jeong JM; Son MJ; Jin CB; Kim HJ; Seo HS
    PPAR Res; 2019; 2019():5317126. PubMed ID: 31781179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erratum: Metabolic and Hepatic Effects of Empagliflozin on Nonalcoholic Fatty Liver Mice [Corrigendum].
    Diabetes Metab Syndr Obes; 2023; 16():2833-2834. PubMed ID: 37736329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Corrigendum to "Alcoholic and Nonalcoholic Liver Disease: Diagnostic Assessment and Therapeutic Perspectives".
    Gitt S; Bihl F; Schepis F; Caputo F; Berenguer M
    Biomed Res Int; 2020; 2020():4305190. PubMed ID: 33224978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corrigendum: Vegetarian diet, food substitution, and nonalcoholic fatty liver.
    Ci Ji Yi Xue Za Zhi; 2018; 30(3):194. PubMed ID: 30069133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functions of Coenzyme Q10 Supplementation on Liver Enzymes, Markers of Systemic Inflammation, and Adipokines in Patients Affected by Nonalcoholic Fatty Liver Disease: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial.
    Farsi F; Mohammadshahi M; Alavinejad P; Rezazadeh A; Zarei M; Engali KA
    J Am Coll Nutr; 2016; 35(4):346-53. PubMed ID: 26156412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonalcoholic fatty liver disease: a systematic review.
    Rinella ME
    JAMA; 2015 Jun; 313(22):2263-73. PubMed ID: 26057287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of dietary carbohydrates and macronutrients in the pathogenesis of nonalcoholic fatty liver disease.
    Lê KA; Bortolotti M
    Curr Opin Clin Nutr Metab Care; 2008 Jul; 11(4):477-82. PubMed ID: 18542010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of bariatric surgeries on nonalcoholic fatty liver disease: Erratum.
    Saudi J Gastroenterol; 2015; 21(5):341. PubMed ID: 26458864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corrigendum to "Dietary Pattern and Macronutrients Profile on the Variation of Inflammatory Biomarkers: Scientific Update".
    Silveira BKS; Oliveira TMS; Andrade PA; Hermsdorff HHM; Rosa COB; Franceschini SDCC
    Cardiol Res Pract; 2018; 2018():9830287. PubMed ID: 30647969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical and Histopathological Evidence on Beneficial Effects of Standardized Extract from Tragopogon graminifolius as a Dietary Supplement in Fatty Liver: Role of Oxidative Stress.
    Sadeghi A; Bahramsoltani R; Rahimi R; Farzaei MH; Farzaei F; Haghighi ZMS; Abdollahi M
    J Diet Suppl; 2018 Mar; 15(2):197-206. PubMed ID: 28759276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the Effect Derived from Silybin with Vitamin D and Vitamin E Administration on Clinical, Metabolic, Endothelial Dysfunction, Oxidative Stress Parameters, and Serological Worsening Markers in Nonalcoholic Fatty Liver Disease Patients.
    Federico A; Dallio M; Masarone M; Gravina AG; Di Sarno R; Tuccillo C; Cossiga V; Lama S; Stiuso P; Morisco F; Persico M; Loguercio C
    Oxid Med Cell Longev; 2019; 2019():8742075. PubMed ID: 31737175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correction: Toyocamycin attenuates free fatty acid-induced hepatic steatosis and apoptosis in cultured hepatocytes and ameliorates nonalcoholic fatty liver disease in mice.
    Takahara I; Akazawa Y; Tabuchi M; Matsuda K; Miyaaki H; Kido Y; Kanda Y; Taura N; Ohnita K; Takeshima F; Sakai Y; Eguchi S; Nakashima M; Nakao K
    PLoS One; 2020; 15(7):e0235729. PubMed ID: 32609746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Corrigendum: Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates.
    Wang PX; Ji YX; Zhang XJ; Zhao LP; Yan ZZ; Zhang P; Shen LJ; Yang X; Fang J; Tian S; Zhu XY; Gong J; Zhang X; Wei QF; Wang Y; Li J; Wan L; Xie Q; She ZG; Wang Z; Huang Z; Li H
    Nat Med; 2017 Oct; 23(10):1241. PubMed ID: 28985205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High coffee intake is associated with lower grade nonalcoholic fatty liver disease: the role of peripheral antioxidant activity.
    Gutiérrez-Grobe Y; Chávez-Tapia N; Sánchez-Valle V; Gavilanes-Espinar JG; Ponciano-Rodríguez G; Uribe M; Méndez-Sánchez N
    Ann Hepatol; 2012; 11(3):350-5. PubMed ID: 22481454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonalcoholic fatty liver and the severity of acute pancreatitis.
    Mikolasevic I; Orlic L; Poropat G; Jakopcic I; Stimac D; Klanac A; Carovic F; Milic S
    Eur J Intern Med; 2017 Mar; 38():73-78. PubMed ID: 27825671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Corrigendum to "Advanced Hepatic Fibrosis in Fatty Liver Disease Linked to Hyperplastic Colonic Polyp".
    Mahamid M; Abu-Elhija O; Yassin T; Nseir W
    Can J Gastroenterol Hepatol; 2017; 2017():9042568. PubMed ID: 29445719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correction: Nonalcoholic fatty liver disease is a risk factor for large-for-gestational-age birthweight.
    Lee SM; Kim BJ; Koo JN; Norwitz ER; Oh IH; Kim SM; Kim SY; Kim GM; Kwak SH; Kim W; Joo SK; Shin S; Vixay C; Park CW; Jun JK; Park JS
    PLoS One; 2019; 14(10):e0224845. PubMed ID: 31665185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.